Literature DB >> 14738457

Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy.

G d'Ettorre1, G Forcina, M Andreotti, L Sarmati, L Palmisano, M Andreoni, S Vella, C M Mastroianni, V Vullo.   

Abstract

A discordant response to highly active antiretroviral therapy (HAART) occurs when CD4 T cell counts are stable or increased over time despite persistently detectable HIV-RNA levels. In order to identify immunological factors affecting discordant treatment responses, a total of 27 HIV-infected patients were studied: (a) 10 naive patients (mean CD4+ = 101.5 cells/microl; mean HIV-RNA = 4.8 log10 copies/ml); (b) seven responder patients (mean CD4+ = 908.9 cells/microl); and (c) 10 discordant patients (mean CD4+ = 396.1 cells/microl; mean HIV-RNA = 5.4 log10 copies/ml). Five healthy blood donors were included as HIV-seronegative controls. The following parameters were evaluated: interleukin (IL)-15 production by monocyte-derived dendritic cells (MDDC) after stimulation with lypopolysaccaride (LPS) and Candida albicans; recall and HIV-1-specific antigen lymphocyte proliferation (LP). Increased levels of IL-15 production by MDDC after stimulation with LPS and C. albicans were found both in discordant patients and responder patients. Conversely, a strong reduction of IL-15 levels was observed in naive patients. Discordant patients developed positive LP responses to C. albicans and HIV-1 p24. LP in response to C. albicans and HIV-1 p24 was also positive in responder patients. Decreased LP response was found in naive patients. In conclusion, HIV-infected patients with discordant viro-immunological responses to HAART present increased levels of IL-15 production by MDDC and enhanced recall and HIV-1-specific antigen LP responses, suggesting an improvement in indices of immune function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738457      PMCID: PMC1808945          DOI: 10.1111/j.1365-2249.2004.02373.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells.

Authors:  Mari Strengell; Sampsa Matikainen; Jukka Sirén; Anne Lehtonen; Don Foster; Ilkka Julkunen; Timo Sareneva
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

2.  Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression.

Authors:  A H Patki; M E Quiñones-Mateu; D Dorazio; B Yen-Lieberman; W H Boom; E K Thomas; M M Lederman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients.

Authors:  Gabriella d'Ettorre; Gabriele Forcina; Miriam Lichtner; Fabio Mengoni; Claudia D'Agostino; Anna P Massetti; Claudio M Mastroianni; Vincenzo Vullo
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

Review 4.  A TH1-->TH2 switch is a critical step in the etiology of HIV infection.

Authors:  M Clerici; G M Shearer
Journal:  Immunol Today       Date:  1993-03

5.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

6.  The Role of Antigen-presenting Cells in HIV Pathogenesis.

Authors:  Claire Chougnet; Gene M. Shearer; Alan L. Landay
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

7.  Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes.

Authors:  H Z Bass; J L Fahey; P Nishanian; R Detels; W Cumberland; M Kemeny; S Plaeger
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

8.  Studies on the production of IL-15 in HIV-infected/AIDS patients.

Authors:  Rasheed Ahmad; Sardar T A Sindhu; Emil Toma; Richard Morisset; Ali Ahmad
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

9.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor.

Authors:  J G Giri; S Kumaki; M Ahdieh; D J Friend; A Loomis; K Shanebeck; R DuBose; D Cosman; L S Park; D M Anderson
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

View more
  1 in total

1.  Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.

Authors:  P Costa; F Bozzano; D Fenoglio; A Beltrame; G Cenderello; A Di Biagio; G Ferrea; G Pagano; A De Maria
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.